Group 1 - The core viewpoint of the news is that the Sci-Tech Innovation Board (STAR Market) is witnessing the first batch of companies transitioning out of the growth tier, with significant revenue and profit growth expected for 2025 [2][3] - As of March 11, all companies on the STAR Market have disclosed their 2025 performance, projecting total revenue of 1.59 trillion yuan, a year-on-year increase of 10.3%, and net profit of 59.1 billion yuan, a year-on-year increase of 28.2% [2] - Six companies, including Cambricon and BeiGene, are expected to successfully turn profitable, with net profits ranging from 80 million yuan to 2.1 billion yuan, and are anticipated to remove the special "U" designation after the 2025 annual report [2][3] Group 2 - Among the six companies, BeiGene leads in revenue, expecting 2025 revenue of 38.205 billion yuan, a 40.4% increase, and a net profit of 1.422 billion yuan, driven by strong sales of its key products [3] - Cambricon achieved a revenue of 6.497 billion yuan in 2025, a substantial increase of 453.21%, marking its first annual profit since its IPO in 2020 [6][8] - Other companies like Orbbec and NIO also reported significant growth, with Orbbec's revenue reaching 941 million yuan (up 66.66%) and NIO's revenue at 2.726 billion yuan (up 108.93%) [8] Group 3 - The STAR Market's growth tier was established to support technology companies with significant breakthroughs and broad commercial prospects, particularly those that are not yet profitable at the time of listing [10] - Since the introduction of the "1+6" policy measures by the China Securities Regulatory Commission, several cutting-edge technology companies have accelerated their listing processes, with 39 companies now included in the growth tier [10] - The establishment of the growth tier enhances the market's inclusivity and attractiveness, catering to different risk preferences among investors [11]

Core Viewpoint - BeiGene (06160) announced a new subscription period for its 2018 Employee Stock Purchase Plan, which will run from March 2, 2026, to August 31, 2026 [1] Group 1 - Eligible employees will be able to purchase shares at a 15% discount to the market price, including American Depositary Shares [1] - The purchase funds will be deducted from the employees' salaries earned during the subscription period [1] - The plan is managed by the company's remuneration committee, aiming to align employee interests with those of shareholders [1]

Summary of the Conference Call on Innovative Pharmaceuticals Industry Overview - The focus of the conference call is on the innovative pharmaceuticals sector, particularly in the context of recent market trends and government policies impacting the industry [1][2][3]. Key Points and Arguments 1. **Market Recovery**: The innovative pharmaceuticals sector has recently experienced a significant rebound, indicating a potential bottoming out of the market [1][2]. 2. **Government Support**: The recent government work report has elevated the status of the biopharmaceutical industry, identifying it as one of the six emerging pillar industries, which includes integrated circuits and aerospace [2][3]. 3. **License-Out Transactions**: In the first quarter of 2026, there have been 49 license-out transactions involving 57 pipelines, totaling nearly $57 billion, with upfront payments exceeding $3.3 billion [3][4]. 4. **Valuation Adjustments**: There has been a notable change in market sentiment regarding business development (BD) transactions, with stock prices not reflecting the positive outcomes of these deals as they did previously [4][5]. 5. **Company Performance**: Companies like BeiGene have reported strong financial results, with 2025 revenues reaching over $5 billion, a 40% year-on-year increase, and a transition from loss to profit [7][8]. 6. **Future Earnings Guidance**: BeiGene has provided optimistic guidance for 2026, projecting revenues to rise to $6.2-$6.4 billion and significant profit growth [8][9]. 7. **Valuation Metrics**: The current valuation of innovative pharmaceutical companies is expected to increase as they transition into profitability, with a shift from price-to-sales (PS) to price-to-earnings (PE) metrics [9][10]. 8. **Investment Recommendations**: It is advised to gradually increase positions in leading innovative pharmaceutical companies such as BeiGene, Innovent Biologics, and others, while also exploring high-potential new technologies and differentiated fields [11][12]. Additional Important Insights - **Market Sentiment**: The overall market sentiment has shifted positively towards innovative pharmaceuticals, with a significant correction in stock prices since mid-2022, providing a more attractive entry point for investors [6][7]. - **Clinical Data Highlights**: Recent clinical data from companies like I-Mab and Rongchang have shown promising results in various cancer treatments, indicating potential breakthroughs in the market [14][15][16]. - **Long-term Outlook**: The innovative pharmaceuticals sector is expected to see continued growth and investment opportunities, driven by strong fundamentals and upcoming clinical data releases [12][16]. This summary encapsulates the key insights and developments discussed during the conference call, highlighting the current state and future prospects of the innovative pharmaceuticals industry.

BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 員工購股計劃 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。本公司宣佈，2018 員工購股計劃的新一輪認購期自2026年3月2日起至2026年8月31日止。合資格僱 員將於認購期結束後購買股份（包括以美國存託股份的形式），購股資金從其認購 期所得薪金中扣除。 2018員工購股計劃概要 2018員工購股計劃使合資格僱員可按市價15%折讓申購股份（包括以美國存託股 份的形式）。僱員可於認購期結束後購買股份，購股資金可從其認購期內所得薪金 中扣除。2018員工購股計劃由董事會薪酬委員會管理。 認購期詳情 申請期： 2026年2月13日至2026年2月28日 認購期： 2026年3月2日至2026年8月31日 2018員工購股計劃項下的認購期通常從每年3月1日及 9月1日 ...

Core Viewpoint - BeiGene (06160) announced a new subscription period for its 2018 Employee Stock Purchase Plan, which will run from March 2, 2026, to August 31, 2026, allowing eligible employees to purchase shares at a 15% discount from market price [1] Group 1 - The 2018 Employee Stock Purchase Plan allows eligible employees to buy shares, including American Depositary Shares, with funds deducted from their salaries earned during the subscription period [1] - The plan is managed by the company's Board Compensation Committee [1] - The company believes that providing employees with the opportunity to gain ownership through the Employee Stock Purchase Plan encourages continued employment and aligns employee interests with those of shareholders, benefiting both the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 員工購股計劃 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。本公司宣佈，2018 員工購股計劃的新一輪認購期自2026年3月2日起至2026年8月31日止。合資格僱 員將於認購期結束後購買股份（包括以美國存託股份的形式），購股資金從其認購 期所得薪金中扣除。 2018員工購股計劃概要 2018員工購股計劃使合資格僱員可按市價15%折讓申購股份（包括以美國存託股 份的形式）。僱員可於認購期結束後購買股份，購股資金可從其認購期內所得薪金 中扣除。2018員工購股計劃由董事會薪酬委員會管理。 認購期詳情 申請期： 2026年2月13日至2026年2月28日 認購期： 2026年3月2日至2026年8月31日 2018員工購股計劃項下的認購期通常從每年3月1日及 9月1日 ...

Investment Rating - The report suggests a positive investment outlook for the targeted protein degradation (TPD) industry, indicating it is at a historical turning point for commercialization, with significant growth potential similar to the ADC sector [1]. Core Insights - The TPD field is transitioning from a scientific concept to a commercial explosion, with key catalysts expected in 2026, including the approval of Arvinas' ARV-471 and BMS's Iberdomide, marking the realization of TPD technology's value after over 20 years of development [1]. - The report highlights the dual-driven technological landscape of PROTAC and molecular glue, with rapid penetration into new therapeutic areas such as autoimmune diseases, showcasing the industry's adaptability and growth potential [2]. - The emergence of AI technologies is accelerating the drug development process in TPD, making this an optimal time for investment as the first PROTAC molecules are set to commercialize [17]. Summary by Sections Investment Logic - TPD is expected to replicate the growth trajectory of ADCs, overcoming barriers associated with traditional small molecule inhibitors by utilizing the UPS and ALPS systems for effective protein degradation [1]. - 2026 is projected to be a pivotal year for commercialization, with significant drug approvals anticipated [1]. Technological Pathways - The report outlines a dual-driven approach with PROTAC and molecular glue technologies, emphasizing their clinical validation and the potential for new therapeutic applications [2]. - The self-immune field is highlighted as a strategic growth area, with companies like Kymera and Monte Rosa developing promising candidates [2]. Competitive Landscape - Key catalysts in 2026 are expected to reshape the competitive landscape, with companies demonstrating platform capabilities and differentiated target strategies likely to enjoy valuation premiums [3]. - The report identifies several leading companies and their promising pipelines, including Arvinas, Nurix, and Monte Rosa, which are positioned to capitalize on upcoming clinical data and market opportunities [3]. Investment Recommendations - The report recommends focusing on late-stage assets nearing commercialization, particularly those from Arvinas and BMS, while also highlighting biotech firms like Monte Rosa and Kymera that are expanding into autoimmune and chronic disease markets [4].

Group 1 - The core viewpoint of the news highlights the recent downturn in the Asia-Pacific market, particularly in the Hong Kong pharmaceutical sector, with the Hong Kong Stock Connect Innovation Drug ETF (159570) experiencing a nearly 2% decline, despite a significant net subscription of 210 million yuan and a total scale exceeding 23.1 billion yuan [1][3] - The high-level meeting has officially categorized innovative drugs as an "emerging pillar industry," emphasizing the acceleration of commercial health insurance development and the promotion of high-quality development in innovative drugs [3] - The approval of Hansoh Pharmaceutical's application for the listing of Amivantamab tablets marks a significant milestone, as it is the first domestically developed third-generation EGFR-TKI in China, with five approved indications since its initial approval in March 2020 [3] Group 2 - In business development news, China Biologic Products announced an exclusive licensing agreement with Sanofi for Rovafatinib, a novel oral small molecule JAK/ROCK inhibitor, with potential payments totaling up to 1.53 billion USD, including an upfront payment of 135 million USD [4] - The Hong Kong Stock Connect Innovation Drug ETF (159570) saw most of its index's popular stocks decline, with notable drops including 5% for 3SBio and over 4% for CanSino Biologics, while Hansoh Pharmaceutical saw a slight increase due to new drug news [4] - The innovative drug sector is experiencing short-term volatility, but the long-term growth potential remains intact, with a focus on the globalization of Chinese pharmaceutical companies and the advancement of innovative technologies [6][9] Group 3 - The focus of the market has shifted from the ability to enter overseas markets to the progress of products in overseas clinical deployments, with key data readouts and milestone achievements becoming critical for future evaluations [7] - Chinese companies are making breakthroughs in frontier technologies such as small nucleic acids and cell therapies, positioning themselves as core assets in global transactions [8] - Leading innovative drug companies are entering a positive cycle of product commercialization and reinvestment in research and development, with expectations for significant performance improvements in the upcoming earnings period [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2026年3月2日， 董事會薪酬委員會根據2016期權及激勵計劃的條款向一百八十八名承授人授出涉 及合共21,197股美國存託股份的受限制股份單位。 授出受限制股份單位 2016期權及激勵計劃項下的受限制股份單位 於2026年3月2日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予一百八 十八名承授人合共21,197股美國存託股份受限制股份單位。該等受限制股份單位 相當於275,561股股份，約佔本公告之日公司發行股份總數的0.02%。 授出受限制股份單位詳情 受限制股份單位詳情如下： 1 授出日期： 2026年3月2日 承授人數目： 一百八十八名 已授出受限制股份單位涉及的 相關股份數目： 275,561 受 ...

Group 1 - The company BeiGene (06160) announced that on March 2, 2026, the Board's Compensation Committee granted a total of 21,200 restricted stock units to 180 grantees under the 2016 Option and Incentive Plan [1] - The granted restricted stock units are equivalent to 275,600 shares, representing approximately 0.02% of the total issued share capital of the company as of the date of the announcement [1]